Thus, in the setting of thrombocytopenia, renal failure, nephropathy, or elevated liver enzymes, or when faced with the differential diagnosis between atypical HELLP syndrome, aHUS, thrombotic thrombocytopenic purpura, nocturnal paroxysmal hemoglobinuria, or any suspicion of systemic microangiopathy, the sFlt‐1/PlGF ratio reduces diagnostic imprecisions and helps to identify the right therapeutic approach (Verlohren et al. 2022; Zeisler et al. 2016; Young et al. 2010; Béranger et al. 2023). This evidence concerns the gene PGF and acute kidney injury.